[(S*)-2-(3-hydroxyphenyl)-1-((2S*,4R*)-4-methyl-5-oxotetrahydrofuran-2-yl)ethyl]carbamic acid tert-butyl ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(S*)-2-(3-hydroxyphenyl)-1-((2S*,4R*)-4-methyl-5-oxotetrahydrofuran-2-yl)ethyl]carbamic acid tert-butyl ester
• 英文别名: [(S*)-2-(3-Hydroxy-phenyl)-1-((2S*,4R*)-4-methyl-5-oxo-tetrahydro-furan-2-yl)-ethyl]-carbamic acid tert-butyl ester；tert-butyl N-[(1S)-2-(3-hydroxyphenyl)-1-[(2S,4R)-4-methyl-5-oxooxolan-2-yl]ethyl]carbamate
• 化学式: C₁₈H₂₅NO₅
• 分子量: 335.4
• InChiKey: GQGHMXPPDQXCSP-UGFHNGPFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-苯基双(三氟甲烷磺酰)亚胺 、 [(S*)-2-(3-hydroxyphenyl)-1-((2S*,4R*)-4-methyl-5-oxotetrahydrofuran-2-yl)ethyl]carbamic acid tert-butyl ester 在 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以86%的产率得到trifluoromethanesulfonic acid 3-[(S*)-2-tert-butoxycarbonylamino-2-((2S*,4R*)-4-methyl-5-oxotetrahydrofuran-2-yl)ethyl]phenyl ester
  参考文献：
  名称：

  Macrocyclic Compounds Useful as Bace Inhibitors

  摘要：

  本发明涉及具有公式(I)的新型大环化合物，其中所有变量如说明书中所定义，大环环中包含的环原子数为14、15、16或17，以自由碱形式或酸加成盐形式存在，以及它们的制备方法、作为药物的使用以及包含它们的药物。

  公开号：

  US20080132477A1
• 作为产物：
  描述：

  [(S*)-2-(3-benzyloxy-phenyl)-1-((2S*,4R*)-4-methyl-5-oxo-tetrahydro-furan-2-yl)-ethyl]-carbamic acid tert-butyl ester 在 钯 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以gives 0.8 g (2.4 mmol, 100%) of the product as a white foam的产率得到[(S*)-2-(3-hydroxyphenyl)-1-((2S*,4R*)-4-methyl-5-oxotetrahydrofuran-2-yl)ethyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  Macrocyclic Compounds Useful as Bace Inhibitors

  摘要：

  本发明涉及式(I)的新型大环化合物，其中所有变量如规范中所定义，大环环中包括的环原子数为14、15、16或17，以自由碱形式或酸盐形式存在，其制备方法，它们作为药物的用途以及包含它们的药物。

  公开号：

  US20080132477A1

文献信息

• [EN] MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF<br/>[FR] COMPOSES MACROCYLIQUES PRESENTANT UNE ACTIVITE D'INHIBITION DE PROTEASE ASPARTIQUE ET UTILISATIONS PHARMACEUTIQUES DE CEUX-CI
  申请人：NOVARTIS AG

  公开号：WO2005003106A1

  公开（公告）日：2005-01-13

  The present invention relates to macrocyclic compounds of formula (I), wherein R1, is (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, hydroxy(C1-6)alkyl, (C1-4)alkylthio(C1-4)alkyl, (C1-6)alkenyl, (C3-­7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, piperidinyl or pyrrolidinyl, R2 and R4, independently, are hydrogen or optionally substituted (C1-8)alkyl, (C3-7) cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, aryl, aryl(C1-4)alkyl, heteroaryl or heteroaryl(C1-4) alkyl, or R2 and R4, together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl group, R3 is hydrogen or (C1-4)alkyl, X1 is CH2, X2 is CH2, O, S, CO, COO, OCO, NHCO, CONH, or NR, R being hydrogen or (C1-4)alkyl, Y is (C1-8)alkylen or (C1-­8)alkylenoxy(C1-6)alkylen, (C1-8)alkenylen or (C1-8)alkenylenoxy(C1-6)alkylen, Ar is a phenyl ring optionally mono- di­ or trisubstituted by, independently, hydroxy or halogen, whereby X1, and X2 are in meta or para position to each other, and either Z is CO, AA is a natural or unnatural alpha-amino-acid, and n is 0 or 1, or Z is S02, AA is an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylen group), and n is 1; processes for the preparation of these compounds; pharmaceutical compositions and combinations comprising the same; and their use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.

  本发明涉及式(I)的大环化合物，其中R1为(C1-8)烷基，(C1-4)烷氧基(C1-4)烷基，羟基(C1-6)烷基，(C1-4)烷基硫基(C1-4)烷基，(C1-6)烯基，(C3-7)环烷基，(C3-7)环烷基(C1-4)烷基，哌啶基或吡咯啉基，R2和R4，独立地，为氢或可选择取代的(C1-8)烷基，(C3-7)环烷基，(C3-7)环烷基(C1-4)烷基，芳基，芳基(C1-4)烷基，杂环芳基或杂环芳基(C1-4)烷基，或R2和R4与它们连接的氮一起形成可选择取代的哌啶基，吡咯啉基，吗啉基或哌嗪基，R3为氢或(C1-4)烷基，X1为CH2，X2为CH2，O，S，CO，COO，OCO，NHCO，CONH或NR，R为氢或(C1-4)烷基，Y为(C1-8)烷基或(C1-8)烷氧基(C1-6)烷基，(C1-8)烯基或(C1-8)烯氧基(C1-6)烷基，Ar为苯环，可选择单取代、双取代或三取代，取代基为羟基或卤素，其中X1和X2在彼此的间位或对位，且Z为CO时，AA为天然或非天然的α-氨基酸，n为0或1；或Z为SO2时，AA为可选择取代的乙烯羰基团（由天然或非天然的α-氨基酸通过用甲基烷基替换氮而得到），n为1；制备这些化合物的方法；包含这些化合物的药物组合物和药物组合物；以及它们在治疗与β-淀粉样蛋白生成和/或聚集相关的神经和血管疾病中的用途。
• Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof
  申请人：Betschart Claudia

  公开号：US20060223745A1

  公开（公告）日：2006-10-05

  The present invention relates to macrocyclic compounds of formula (I), wherein R 1 , is (C 1-8 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, hydroxy(C 1-6 )alkyl, (C 1-4 )alkylthio(C 1-4 )alkyl, (C 1-6 )alkenyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, piperidinyl or pyrrolidinyl, R 2 and R 4 , independently, are hydrogen or optionally substituted (C 1-8 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, aryl, aryl(C 1-4 )alkyl, heteroaryl or heteroaryl(C 1-4 )alkyl, or R 2 and R 4 , together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl group, R 3 is hydrogen or (C 1-4 )alkyl, X 1 is CH 2 , X 2 is CH 2 , O, S, CO, COO, OCO, NHCO, CONH, or NR, R being hydrogen or (C 1-4 )alkyl, Y is (C 1-8 )alkylen or (C 1-8 )alkylenoxy(C 1-6 )alkylen, (C 1-8 )alkenylen or (C 1-6 )alkenylenoxy(C 1-6 )alkylen, Ar is a phenyl ring optionally mono- di or trisubstituted by, independently, hydroxy or halogen, whereby X 1 , and X 2 are in meta or para position to each other, and either Z is CO, AA is a natural or unnatural alpha-amino-acid, and n is 0 or 1, or Z is SO 2 , AA is an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylen group), and n is 1; processes for the preparation of these compounds; pharmaceutical compositions and combinations comprising the same; and their use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.

  本发明涉及式（I）的大环化合物，其中R1为（C1-8）烷基，（C1-4）烷氧基（C1-4）烷基，羟基（C1-6）烷基，（C1-4）烷基硫基（C1-4）烷基，（C1-6）烯基，（C3-7）环烷基，（C3-7）环烷基（C1-4）烷基，哌啶基或吡咯烷基，R2和R4独立地为氢或可选取代的（C1-8）烷基，（C3-7）环烷基，（C3-7）环烷基（C1-4）烷基，芳基，芳基（C1-4）烷基，杂环芳基或杂环芳基（C1-4）烷基，或R2和R4与它们附着的氮一起形成可选取代的哌啶基，吡咯烷基，吗啉基或哌嗪基，R3为氢或（C1-4）烷基，X1为CH2，X2为CH2，O，S，CO，COO，OCO，NHCO，CONH或NR，其中R为氢或（C1-4）烷基，Y为（C1-8）烷基或（C1-8）烷氧基（C1-6）烷基，（C1-8）烯基或（C1-6）烯氧基（C1-6）烷基，Ar为苯环，可选取代，独立地为羟基或卤素，其中X1和X2在彼此的间位或对位，且Z为CO时，AA为天然或非天然α-氨基酸，n为0或1，或Z为SO2时，AA为可选取代的乙烯羰基（通过将氮替换为甲基烷基而来自天然或非天然α-氨基酸），n为1；制备这些化合物的方法；包含它们的制药组合物和组合物；以及它们在治疗与β-淀粉样蛋白生成和/或聚集有关的神经和血管疾病中的用途。
• MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF
  申请人：Betschart Claudia

  公开号：US20080070885A1

  公开（公告）日：2008-03-20

  The present invention relates to macro-cyclic compounds of formula (I), wherein R 1 , is (C 1-8 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, hydroxy(C 1-6 )alkyl, (C 1-4 )alkylthio(C 1-4 )alkyl, (C 1-6 )alkenyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, piperidinyl or pyrrolidinyl, R 2 and R 4 , independently, are hydrogen or optionally substituted (C 1-8 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, aryl, aryl(C 1-4 )alkyl, heteroaryl or heteroaryl(C 1-4 )alkyl, or R 2 and R 4 , together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl group, R 3 is hydrogen or (C 1-4 )alkyl, X 1 is CH 2 , X 2 is CH 2 , O, S, CO, COO, OCO, NHCO, CONH, or NR, R being hydrogen or (C 1-4 )alkyl, Y is (C 1-8 )alkylen or (C 1-8 )alkylenoxy(C 1-6 )alkylen, (C 1-8 )alkenylen or (C 1-8 )alkenylenoxy(C 1-6 )alkylen, Ar is a phenyl ring optionally mono- di or trisubstituted by, independently, hydroxy or halogen, whereby X 1 , and X 2 are in meta or para position to each other, and either Z is CO, AA is a natural or unnatural alpha-amino-acid, and n is 0 or 1, or Z is S0 2 , AA is an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylen group), and n is 1; processes for the preparation of these compounds; pharmaceutical compositions and combinations comprising the same; and their use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.

  本发明涉及公式（I）的大环化合物，其中R1是（C1-8）烷基，（C1-4）烷氧基（C1-4）烷基，羟基（C1-6）烷基，（C1-4）烷基硫基（C1-4）烷基，（C1-6）烯基，（C3-7）环烷基，（C3-7）环烷基（C1-4）烷基，哌啶基或吡咯烷基，R2和R4分别是氢或可选择取代的（C1-8）烷基，（C3-7）环烷基，（C3-7）环烷基（C1-4）烷基，芳基，芳基（C1-4）烷基，杂环芳基或杂环芳基（C1-4）烷基，或R2和R4与它们连接的氮一起形成可选择取代的哌啶基，吡咯烷基，吗啉基或哌嗪基，R3是氢或（C1-4）烷基，X1是CH2，X2是CH2，O，S，CO，COO，OCO，NHCO，CONH或NR，其中R是氢或（C1-4）烷基，Y是（C1-8）烷基或（C1-8）烷氧基（C1-6）烷基，（C1-8）烯基或（C1-8）烯氧基（C1-6）烷基，Ar是苯环，可选择单取代，二取代或三取代，独立的取代基为羟基或卤素，其中X1和X2相对于彼此处于间位或对位，且Z要么是CO，AA是天然或非天然α-氨基酸，n为0或1，要么Z是S02，AA是可选择取代的乙烯基羰基基团（通过将氮替换为甲基烷基团从天然或非天然α-氨基酸衍生而来），n为1；制备这些化合物的方法；包括这些化合物的药物组合物和制剂；以及它们在治疗与β-淀粉样蛋白生成和/或聚集有关的神经和血管疾病中的用途。
• MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS
  申请人：Novartis AG

  公开号：EP1851208A1

  公开（公告）日：2007-11-07
• [EN] MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS<br/>[FR] COMPOSES MACROCYCLIQUES SERVANT D'INHIBITEURS DE BACE
  申请人：NOVARTIS AG

  公开号：WO2006074950A1

  公开（公告）日：2006-07-20

  [EN] The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
  [FR] L'invention concerne des composés macrocycliques de formule (I), dans laquelle toutes les variables sont telles que définies dans la spécification, le nombre d'atomes cycliques inclus dans l'anneau macrocyclique étant de 14, 15, 16 ou 17, sous forme de base libre ou de sel d'addition acide. La présente invention porte également sur leur préparation, sur leur utilisation en tant que médicaments et sur des médicaments les contenant.